Cargando…

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers

BACKGROUND: Glucose fluctuations including robust postprandial hyperglycemia are a risk for promoting atherosclerosis and diabetic complications. The α-glucosidase inhibitors and the dipeptidyl peptidase-4 (DPP-4) inhibitors have been found to effectively decrease postprandial hyperglycemia independ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishimoto, Miyako, Noda, Mitsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307032/ https://www.ncbi.nlm.nih.gov/pubmed/22189184 http://dx.doi.org/10.1186/1475-2840-10-115

Ejemplares similares

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study
por: Ihana, Noriko, et al.
Publicado: (2014)

Continuous Glucose Monitoring in Patients with Abnormal Glucose Tolerance during Pregnancy: A Case Series
por: Tonoike, Mie, et al.
Publicado: (2016)

Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome
por: Amagai, Mari, et al.
Publicado: (2017)

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
por: Sakamoto, Masaya, et al.
Publicado: (2012)

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study
por: Shimabukuro, Michio, et al.
Publicado: (2017)

Diabetes care: After the Great East Japan Earthquake
por: Kishimoto, Miyako, et al.
Publicado: (2013)

The difficulties of interprofessional teamwork in diabetes care: a questionnaire survey
por: Kishimoto, Miyako, et al.
Publicado: (2014)

The Great East Japan Earthquake: Experiences and Suggestions for Survivors with Diabetes (perspective)
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance
por: Masuda, Kiyomi, et al.
Publicado: (2011)

The factors that limit activities of certified diabetes educators in Japan: a questionnaire survey
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia
por: Kitano, Daisuke, et al.
Publicado: (2013)

Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes
por: Ko, Hwa Yeon, et al.
Publicado: (2023)

Prediction of 90-day mortality in patients without diabetes by severe hypoglycemia: blood glucose level as a novel marker of severity of underlying disease
por: Tsujimoto, Tetsuro, et al.
Publicado: (2014)

Continuous Glucose Monitoring as an Additional Tool in Early Cystic Fibrosis-Related Diabetes Monitoring and in Evaluation of Short-Term Sitagliptin Response
por: Sebastian-Valles, Fernando, et al.
Publicado: (2023)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients
por: Kubo, Sayaka, et al.
Publicado: (2010)

Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up
por: Nakamura, Takashi, et al.
Publicado: (2016)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease
por: Wiciński, Michał, et al.
Publicado: (2018)

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
por: Kodera, Ryo, et al.
Publicado: (2017)

Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2013)

Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes
por: Wakasugi, Satomi, et al.
Publicado: (2021)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking
por: Ramírez, E., et al.
Publicado: (2018)

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
por: Katakami, Naoto, et al.
Publicado: (2018)

Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients
por: Hariya, Natsuyo, et al.
Publicado: (2014)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Stability-Indicating RP-HPLC Method for Estimation of Miglitol in Bulk and Tablets
por: Shrivastava, B., et al.
Publicado: (2010)

Review: Miglitol has potential as a therapeutic drug against obesity
por: Sugimoto, Satoru, et al.
Publicado: (2015)

Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
por: Salehi, Marzieh, et al.
Publicado: (2012)

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus
por: Nomura, Shosaku, et al.
Publicado: (2011)

Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial
por: Iijima, Takahiro, et al.
Publicado: (2020)

Continuous Glucose Monitoring for the Diagnosis of Gestational Diabetes Mellitus: A Pilot Study
por: Di Filippo, Daria, et al.
Publicado: (2022)

Effects of sitagliptin beyond glycemic control: focus on quality of life
por: Sakamoto, Yoshiko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_73a29o0janrt12e4g6nku4jnaq